文献速递胸部肿瘤放疗

治疗前中性粒细胞与淋巴细胞比值与接受立体定向体部放疗的局限性非小细胞肺癌总死亡率相关

Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
PubMed 文献 · Radiother Oncol · 2019-02-15

该研究评估治疗前中性粒细胞与淋巴细胞比值(NLR)与接受立体定向体部放疗(SBRT)的局限性非小细胞肺癌患者总生存及复发的关系。训练队列中NLR>3.6与死亡率在单变量和多变量分析中均相关,并在另外两家机构治疗的独立验证队列中得到验证。二次分析发现治疗后NLR较治疗前显著升高且与死亡率相关。

要点

  • 治疗前NLR>3.6与接受SBRT的局限性非小细胞肺癌患者死亡率相关。
  • 该关联在另外两家机构治疗的独立验证队列中得到验证。
  • 治疗后NLR较治疗前显著升高,且与死亡率相关。

核心结论

  • 治疗前NLR>3.6与接受SBRT的局限性非小细胞肺癌患者死亡率相关。
  • 该发现在另外两家机构治疗的独立队列中得到验证。
  • 治疗后NLR较治疗前显著升高,且与总生存相关。

研究设计与样本

  • 训练队列纳入156例患者和166个肿瘤,中位随访13.4个月。
  • 治疗前NLR在开始SBRT前6个月内获取,评估其与总生存及原发肿瘤、区域和远处复发的关系。
  • 采用多变量Cox回归评估治疗前NLR作为死亡预测因素。
  • 在另外两家机构治疗的独立队列中验证发现。
  • 二次分析评估训练队列中治疗后NLR与死亡率的关系。

主要发现

  • 按中位数二分后,NLR>3.6在单变量分析中与死亡率相关(p=0.010),在多变量分析中亦相关(p=0.023)。
  • 验证队列中NLR>3.6在单变量分析中与死亡率相关(p=0.031),在多变量分析中亦相关(p=0.007)。
  • 训练队列二次分析中,治疗后NLR较治疗前显著升高(p<0.001)。
  • 训练队列二次分析中,治疗后NLR在单变量分析中与死亡率相关(p=0.005),在多变量分析中亦相关(p=0.010)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neutrophil-lymphocyte ratio (NLR) has been associated with mortality in several disease sites. We hypothesized that NLR is associated with inferior outcomes in localized non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). METHODS: We evaluated the association of pre-treatment NLR, obtained within 6 months of starting SBRT, with overall survival, as well as primary tumor, regional, and distant recurrence. Multivariate Cox regression was then used to assess pre-treatment NLR as a predictor of mortality. We validated our findings in an independent cohort of patients treated at two other institutions. In a secondary analysis, we also evaluated the association of post-treatment NLR with mortality in the training cohort. RESULTS: A total of 156 patients and 166 tumors were included in the training cohort with a median follow-up of 13.4 months. After dichotomization by median, NLR > 3.6 was associated with mortality on univariate (p = 0.010) and multivariate analysis (p = 0.023). In the validation cohort, NLR > 3.6 was similarly associated with mortality on univariate (p = 0.031) and multivariate (p = 0.007) analysis. In a secondary analysis in the training cohort, we found post-treatment NLR was significantly increased compared to pre-treatment NLR (p < 0.001) and associated with mortality on univariate analysis (p = 0.005) and multivariate analysis (p = 0.010). CONCLUSIONS: Pre-treatment NLR > 3.6 is associated with mortality in patients treated with SBRT. This finding was validated in an independent cohort of patients treated at two other institutions. Additionally, post-treatment NLR was significantly increased from pre-treatment and associated with overall survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sebastian N, Wu T, Bazan J, et al. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2019. PMID: 31005209. doi:10.1016/j.radonc.2019.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。